Compare EQT Corporation Common Stock (EQT) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
EQT Corporation Common Stock vs Repligen Corporation Common Stock — how do they compare? EQT Corporation Common Stock trades at $52.43 (market cap $34.05B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B). The key difference: EQT Corporation Common Stock is far larger — about 3.1× Repligen Corporation Common Stock's market cap, and EQT Corporation Common Stock pays a 1.21% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold EQT Corporation Common Stock for 1 Days and Repligen Corporation Common Stock for 0 Days on average.
| EQT | RGEN | |
|---|---|---|
Market Cap | $34.05B | $11.14B |
Volume | 4,662,584 | 1,259,263 |
Sector | Energy | Health |
52-Week High | $67.93 | $194.57 |
52-Week Low | $48.56 | $102.87 |
Typical Hold Time | 1 Days | 0 Days |
Enterprise Value | $39.59B | $11.02B |
Dividend Yield | 1.21% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EQT trades at $54.43, up 2.27% today, with a bullish technical outlook and strong analyst consensus. The stock benefits from robust profitability, with a net income margin of 28.61% and a P/E ratio of 12.63. Recent news highlights a dividend increase and positive natural gas market tailwinds, while institutional buying activity supports sentiment. Earnings have mostly beaten expectations, with Q3 2026 results pending.
The outlook for EQT is positive, driven by operational efficiency, favorable natural gas demand, and a strong balance sheet. Risks include commodity price volatility and execution of growth plans. With a consensus price target of $70.33 implying significant upside, the stock presents a compelling opportunity for investors seeking exposure to the energy sector.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About EQT Corporation Common Stock
EQT produces and transports natural gas, with production and midstream operations in the Appalachian Basin. Its operations are concentrated in Pennsylvania, West Virginia, and Ohio.
Read more on EQT →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
